Literature DB >> 30879368

Fetal arrhythmias: diagnosis and treatment.

Shi-Min Yuan1.   

Abstract

Fetal arrhythmias are common, and they may resolve spontaneously in majority of the cases. Sustained fetal arrhythmias associated with major structural heart disorders, hydrops fetalis, and fetal heart failure warrant intrauterine pharmaceutical conversion of heart rhythm or early pacemaker implant in order to avoid fetal demise. Fetal atrial flutter (AF) and supraventricular tachycardia (SVT) resemble in terms of the effects of intrauterine therapies. Digoxin is more suitable for rhythm conversion of fetal AF and SVT in fetuses free of hydrops fetalis, while sotalol shows better effects for those with hydrops fetalis. In fetal cases of atrioventricular blocks, an etiological treatment for the maternal antibody exposure by steroids could be an alternative remedy. In this article, the clinical diagnosis and treatment of fetal arrhythmias are presented, and advantages and disadvantages of antiarrhythmic agents for fetal arrhythmias are compared.

Entities:  

Keywords:  Antiarrhythmia agents; arrhythmias; diagnosis; fetus

Mesh:

Substances:

Year:  2019        PMID: 30879368     DOI: 10.1080/14767058.2018.1555804

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  3 in total

1.  Efficacy and Safety of Various First-Line Therapeutic Strategies for Fetal Tachycardias: A Network Meta-Analysis and Systematic Review.

Authors:  Jiangwei Qin; Zhengrong Deng; Changqing Tang; Yunfan Zhang; Ruolan Hu; Jiawen Li; Yimin Hua; Yifei Li
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

2.  Clinical and genetic spectrum of neonatal arrhythmia in a NICU.

Authors:  Yi Dai; Rong Yin; Lin Yang; Zhi-Hua Li
Journal:  Transl Pediatr       Date:  2021-10

3.  Fetal Atrial Flutter Associated with Atrial Septal Aneurysm.

Authors:  Fuanglada Tongprasert; Suchaya Luewan; Kasemsri Srisupundit; Theera Tongsong
Journal:  Diagnostics (Basel)       Date:  2022-07-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.